Nashville, Tenn. (Vocus) October 8, 2009
A patient who had inoperable, stage 4, colon cancer is free of any detectable malignancy after using a new treatment offered by NeoPlas Innovation. All evidence of disease was gone four months after he began the lovastatin and interferon combination. Now six months into treatment, he remains free of any signs of cancer, and all previous digestive symptoms have been resolved. He is tolerating the treatment well; his only side effect is minor fatigue.
The patient, who is in his late fifties, was diagnosed with extensive cancer of the lower colon in early 2008. Initially his doctors recommended an operation to remove all the organs of his lower abdomen and pelvis. They abandoned this option, however, after determining he would have been unlikely to survive the procedure. Chemotherapy was tried but was ineffective. He visited NeoPlas Innovation's Nashville clinic in the spring of 2009 and began its outpatient treatment.
The treatment he's using was developed by Dr. Stephen Cantrell to battle his own malignant melanoma in 2000. Then a 33-year-old craniofacial and maxillofacial surgeon, Cantrell fought his recurring cancer with multiple surgeries, a cancer vaccine's clinical trial and interferon. After these failed to stop the aggressive malignancy's spread, the surgeon was told he had six weeks to live.
Refusing to accept that prognosis, he searched the medical literature for anything that was new or overlooked. He made an educated guess about trying a combination of lovastatin and interferon. Because of his terminal prognosis, he did something he would never ask of a patient. He experimented on himself with an untested treatment, keeping careful notes and becoming the guinea pig.
After four weeks of the combination, scans showed no remaining evidence of tumors from his melanoma. That was nine years ago, and there has been no evidence of cancer since. (He continues to take low, maintenance doses of both medicines.)
Patients with other cancers began requesting the new drug combination soon after Cantrell's recovery. Continuing to see its potential in those patients, Cantrell left his surgical practice to devote his career to developing the treatment.
Patients from 28 states and four countries have now used the new combination with promising results. They are being treated for extremely aggressive cancers, such as pancreatic, colon, renal, some sarcomas, mesothelioma, melanoma and others. Eventually Cantrell hopes to implement formal clinical trials, but helping individuals remains his priority.
The treatment's medicines have the advantage of being safe and well tolerated. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression).
NeoPlas Innovation's web site, http://www.neoplas.org, provides detailed information about the treatment. Additionally, the clinic can be reached at (615) 371-8100.
For information, contact:
731-989-8019 or 731-608-7650
# # #